Stockreport

Sanofi Autoimmune Pipeline Grows As Market Weighs Valuation And Momentum [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF Sanofi has secured global exclusive rights to Kali Therapeutics' trispecific antibody KT501 for autoimmune diseases, including a first in human program for rheumatoid a [Read more]